Skip to Content

Enablex (darifenacin) Disease Interactions

There are 5 disease interactions with Enablex (darifenacin):

Major

Darifenacin (applies to Enablex) gastric retention

Major Potential Hazard, Moderate plausibility. Applicable conditions: Gastrointestinal Obstruction, Ulcerative Colitis, Myasthenia Gravis, Constipation

Darifenacin is contraindicated in patients with gastric retention. Darifenacin, like other anticholinergic drugs, may decrease gastrointestinal motility and should be used with caution in patients with gastrointestinal obstructive disorders and conditions such as severe constipation, ulcerative colitis, and myasthenia gravis because of the risk of gastric retention.

Major

Darifenacin (applies to Enablex) glaucoma

Major Potential Hazard, Moderate plausibility. Applicable conditions: Glaucoma (Narrow Angle)

Darifenacin is contraindicated in patients with uncontrolled narrow-angle glaucoma. It is recommended to use darifenacin with caution in patients being treated for narrow-angle glaucoma and only where the potential benefits outweigh the risks.

Major

Darifenacin (applies to Enablex) urinary retention

Major Potential Hazard, Moderate plausibility.

Darifenacin is contraindicated in patients with urinary retention. Darifenacin is a competitive muscarinic receptor antagonist. It is recommended to use darifenacin with caution in patients with clinically significant bladder outflow obstruction because of the risk of urinary retention.

Moderate

Darifenacin (applies to Enablex) CNS effects

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Headache, Altered Consciousness

Darifenacin is associated with anticholinergic central nervous system (CNS) effects. Patients should be monitored for signs of anticholinergic CNS effects, particularly after the initiation of treatment or if the dose is increased. It is recommended to reduce the dose or discontinue treatment if patients experience anticholinergic CNS effects. Care should be exercised when prescribing this agent to patients presenting headache, confusion, hallucinations, or somnolence as these might worsen with the use of darifenacin.

Moderate

Darifenacin (applies to Enablex) liver disease

Moderate Potential Hazard, Moderate plausibility.

Darifenacin is extensively metabolized by the liver following oral dosing. The daily dose of darifenacin should not exceed 7.5 mg for patients with moderate hepatic impairment (Child-Pugh B). Darifenacin has not been studied in patients with severe hepatic impairment (Child-Pugh C) and therefore is not recommended for use in this patient population. No dose adjustment is recommended for patients with mild hepatic impairment (Child-Pugh A).

Enablex (darifenacin) drug interactions

There are 349 drug interactions with Enablex (darifenacin)

Enablex (darifenacin) alcohol/food interactions

There is 1 alcohol/food interaction with Enablex (darifenacin)

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.